Cerebral Phospho-Tau Acts Synergistically with Soluble Aß42 Leading to Mild Cognitive Impairment in AAV-AD Rats.

Souchet, B; Audrain, M; Gu, Y; Lindberg, M F; Orefice, N S; Rey, E; Cartier, N; Janel, N; Meijer, L; Braudeau, J

Souchet, B; Audrain, M; Gu, Y; Lindberg, M F; Orefice, N S; Rey, E; Cartier, N; Janel, N; Meijer, L; Braudeau, J.

Affiliation

Souchet B; Jérôme Braudeau, AgenT SAS, Evry 91000, France, jerome.braudeau@agent-biotech.com.

J Prev Alzheimers Dis ; 9(3): 480-490, 2022.

Article in En | MEDLINE | ID: mdl-35841249

Subject(s)

Alzheimer Disease; Cognitive Dysfunction; Alzheimer Disease/diagnosis; Amyloid beta-Peptides; Animals; Cognitive Dysfunction/psychology; Humans; Peptide Fragments; Prodromal Symptoms; Rats; tau Proteins/metabolism

Key words

AAV-AD rat; Aß42; DYRK1A; Hyperphosphorylated tau; leucettine; mild cognitive impairment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: J Prev Alzheimers Dis Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google